Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market

Table of Content

1. Introduction
   • Definition of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market
   • Scope of the Report
2. Methodology
   • Executive Summary
   • Market Overview
   • Market Definition and Segmentation
3. Market Dynamics
   • Drivers
   • Restraints
   • Opportunities
   • Porter's Five Forces Analysis
   • PESTEL Analysis
4. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market, By Treatment Modalities:
   • EGFR Tyrosine Kinase Inhibitors (TKIs)
   • First-generation: erlotinib, gefitinib
   • Second-generation: afatinib, dacomitinib, neratinib
   • Third-generation: osimertinib
5. Combination Therapies: EGFR-TKIs with other modalities (ICIs, chemotherapy, targeted agents)
   • Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market, By EGFR Mutation Status:
   • EGFR-Activating Mutations (exon 19 deletions, exon 21 L858R mutations)
   • EGFR Resistance Mutations (T790M mutation)
6. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market, By End User:
   • Hospitals and Clinics
   • Oncologists and Pulmonologists
   • Pathology Laboratories
   • Patients and Caregivers
   • Pharmaceutical Companies
   • Research Institutions and Academia
7. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market, By Geography
   • North America
     • United States
     • Canada
   • Europe
     • United Kingdom
     • Germany
     • France
     • Spain
     • Italy
     • Rest of Europe
   • Asia-Pacific
     • China
     • Japan
     • India
     • South Korea
     • Australia
     • Rest of Asia-Pacific
   • Latin America
     • Brazil
     • Mexico
     • Rest of Latin America
   • Middle East & Africa
     • Saudi Arabia
     • United Arab Emirates
     • South Africa
     • Rest of Middle East & Africa
8. Competitive Landscape
9. Company Profiles
   • AstraZeneca PLC
     • Company Overview
     • Product Portfolio and Description
     • Key Highlights
     • Financial Overview
   • Roche Holding AG
   • Bristol-Myers Squibb Company
   • Boehringer Ingelheim International GmbH
   • Pfizer Inc.
   • Merck & Co., Inc.
   • Eli Lilly and Company
   • Takeda Pharmaceutical Company Limited
   • Novartis International AG
   • Johnson & Johnson
10. Conclusion and Future Outlook
11. Appendix
    • Research Methodology
    • About the Pharmanucleus

12. Disclaimer